Computational biology market seen hitting $27.22 billion by 2035

Market Research Future projects the global computational biology market will more than triple from 2026 to 2035, fueled by multi-omics data growth, AI foundation models and broader regulatory acceptance of in-silico evidence. North America leads now, while Asia-Pacific is expected to grow fastest.

Why it matters: - The computational biology market is moving from niche research support to core life-science infrastructure. - The shift could speed drug discovery, reduce early-stage screening costs and reshape how companies and regulators use biological data. - Market Research Future projects the global market will reach $27.22 billion by 2035, up from $8.71 billion in 2026.

What happened: - Market Research Future released a forecast calling for 13.5% compound annual growth from 2026 through 2035. - The market base was estimated at $7.71 billion in 2025. - The forecast was issued Sept. 21, 2026. - The report says the growth outlook is driven by multi-omics data, AI foundation models, cloud computing and regulatory acceptance of computational evidence.

The details: - Multi-omics output from genomics, proteomics, metabolomics and transcriptomics is growing faster than institutional infrastructure can absorb. - The report says multi-omics data volume growth adds an estimated 2.8 percentage points to the market CAGR. - AI tools such as transformer-based genome language models and GPU-accelerated molecular docking are changing early-stage drug discovery economics. - Machine learning and AI in biology add an estimated 2.5 percentage points to CAGR. - The FDA Modernization Act 2.0 removed the statutory requirement for animal testing in drug applications, helping legitimize in-silico evidence. - Cloud-native pipelines and exascale high-performance computing are lowering the barrier to large-scale biological simulation. - In 2025, cellular and biological simulation was the largest application segment at 29.8% share. - Drug discovery and disease modelling was the fastest-growing application segment, forecast at a 16.4% CAGR through 2035. - Preclinical drug development generated $1.42 billion in 2025 revenue. - Clinical trials and human body simulation is projected to grow at a 14.1% CAGR. - Databases held the largest tool share in 2025 at 33.4%. - Analysis software and services is the fastest-growing tool segment, projected at a 15.5% CAGR. - Infrastructure and hardware accounted for $1.86 billion in 2025. - Contract and outsourced services represented 48.4% of delivery spend in 2025. - In-house delivery is forecast to grow at a 16.8% CAGR. - Academics remained the largest end-user group in 2025 at 41.0% share. - Industry and commercial buyers are the fastest-growing end-user group, expanding at a 15.3% CAGR. - Government and regulatory users accounted for $1.13 billion in 2025.

Between the lines: - The market is benefiting from a broader reordering of life-science R&D around data platforms instead of standalone lab workflows. - Dassault Systèmes and Certara spent more than $900 million on R&D across 2024 and 2025 to rebuild platforms around foundation-model architectures. - Siemens' $5.1 billion acquisition of Dotmatics signaled that industrial software vendors now view life-science data as core infrastructure. - The National Institutes of Health committed roughly $4.1 billion annually to data-intensive biomedical research infrastructure, with much of it flowing into cloud-native analysis pipelines. - NIH extramural awards exceeded $33 billion in 2024. - Market Research Future estimates the market is moderately concentrated, with a Herfindahl-Hirschman Index of 700 to 900 and the top five vendors holding about 30% to 36% of global revenue. - North America led global revenue in 2025 with a 39.3% share, or about $3.03 billion. - Europe ranked second with 26.8% of global revenue. - Asia-Pacific is projected to be the fastest-growing region at a 17.1% CAGR through 2035. - The Middle East and Africa held about $0.32 billion in 2025.

What's next: - The report expects new demand in regulator-ready model qualification, emerging-market genomics build-out and federated data monetization. - Asia-Pacific growth is expected to be supported by national supercomputing programs in China, Japan and India. - The report says future competition will center less on algorithm novelty and more on validated, regulator-ready data pipelines. - Key companies named in the report include Dassault Systèmes, Siemens, Certara, Schrödinger, Thermo Fisher Scientific, Illumina, Simulations Plus, Genedata, Chemical Computing Group, Insilico Medicine and Instem. - Request a free sample - Read the detailed report